AU2019266525B2 - Cyclopentane compounds - Google Patents

Cyclopentane compounds Download PDF

Info

Publication number
AU2019266525B2
AU2019266525B2 AU2019266525A AU2019266525A AU2019266525B2 AU 2019266525 B2 AU2019266525 B2 AU 2019266525B2 AU 2019266525 A AU2019266525 A AU 2019266525A AU 2019266525 A AU2019266525 A AU 2019266525A AU 2019266525 B2 AU2019266525 B2 AU 2019266525B2
Authority
AU
Australia
Prior art keywords
fluorophenyl
cyclopentyl
compound
piperidyl
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019266525A
Other languages
English (en)
Other versions
AU2019266525A1 (en
Inventor
Jenny Susanna Marika Lindhagen
Grigorios Nikitidis
Weitao Pan
Xiaolin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dizal Jiangsu Pharmaceutical Co Ltd
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of AU2019266525A1 publication Critical patent/AU2019266525A1/en
Application granted granted Critical
Publication of AU2019266525B2 publication Critical patent/AU2019266525B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2019266525A 2018-05-11 2019-05-09 Cyclopentane compounds Active AU2019266525B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/086503 2018-05-11
CN2018086503 2018-05-11
PCT/EP2019/061888 WO2019215268A1 (en) 2018-05-11 2019-05-09 Cyclopentane compounds

Publications (2)

Publication Number Publication Date
AU2019266525A1 AU2019266525A1 (en) 2020-11-26
AU2019266525B2 true AU2019266525B2 (en) 2024-06-13

Family

ID=66542241

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019266525A Active AU2019266525B2 (en) 2018-05-11 2019-05-09 Cyclopentane compounds

Country Status (16)

Country Link
US (2) US11274091B2 (enExample)
EP (1) EP3790870B1 (enExample)
JP (1) JP7418354B2 (enExample)
KR (1) KR102806779B1 (enExample)
CN (1) CN112424182B (enExample)
AR (1) AR115382A1 (enExample)
AU (1) AU2019266525B2 (enExample)
BR (1) BR112020023065A2 (enExample)
CA (1) CA3099507A1 (enExample)
DK (1) DK3790870T3 (enExample)
ES (1) ES2944735T3 (enExample)
MX (1) MX2020012065A (enExample)
PT (1) PT3790870T (enExample)
TW (1) TWI830733B (enExample)
UY (1) UY38229A (enExample)
WO (1) WO2019215268A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI830733B (zh) * 2018-05-11 2024-02-01 中國大陸商迪哲(江蘇)醫藥有限公司 環戊烷化合物
JP7594274B2 (ja) * 2019-10-24 2024-12-04 国立大学法人大阪大学 難聴の予防および/または治療用医薬組成物
WO2025008249A1 (en) 2023-07-06 2025-01-09 Basf Se Triazole compounds for the control of invertebrate pests

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004017930A1 (de) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
EP1753740A2 (en) * 2004-05-21 2007-02-21 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
RU2481336C2 (ru) * 2006-07-06 2013-05-10 Эррэй Биофарма Инк. Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт
TW200940542A (en) * 2008-01-09 2009-10-01 Array Biopharma Inc Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
PL2370442T3 (pl) * 2008-11-26 2013-08-30 Pfizer 3-Aminocyklopentanokarboksamidy jako modulatory receptora chemokiny
US7893099B2 (en) * 2009-06-11 2011-02-22 Hoffman-La Roche Inc. Cyclopentane derivatives
EP2368876A1 (en) * 2010-03-01 2011-09-28 Sanofi Derivatives of aminoindanes, their preparation and their application in therapeutics
EP3010916B1 (en) * 2013-06-21 2017-09-27 Merck Patent GmbH 1,3-diaminocyclopentane carboxamide derivatives
MX2016001134A (es) * 2013-07-29 2016-04-29 Merck Patent Gmbh Derivados 1,3-disustituidos de ciclopentano.
TWI830733B (zh) * 2018-05-11 2024-02-01 中國大陸商迪哲(江蘇)醫藥有限公司 環戊烷化合物

Also Published As

Publication number Publication date
US20220194922A1 (en) 2022-06-23
EP3790870B1 (en) 2023-04-19
KR20210018287A (ko) 2021-02-17
TWI830733B (zh) 2024-02-01
UY38229A (es) 2019-11-29
KR102806779B1 (ko) 2025-05-12
CN112424182A (zh) 2021-02-26
US20210070733A1 (en) 2021-03-11
MX2020012065A (es) 2021-02-26
DK3790870T3 (da) 2023-05-08
CA3099507A1 (en) 2019-11-14
JP2021523178A (ja) 2021-09-02
AR115382A1 (es) 2021-01-13
PT3790870T (pt) 2023-05-05
CN112424182B (zh) 2023-05-23
JP7418354B2 (ja) 2024-01-19
AU2019266525A1 (en) 2020-11-26
US11274091B2 (en) 2022-03-15
TW202016087A (zh) 2020-05-01
BR112020023065A2 (pt) 2021-02-02
US12378218B2 (en) 2025-08-05
WO2019215268A1 (en) 2019-11-14
ES2944735T3 (es) 2023-06-23
EP3790870A1 (en) 2021-03-17

Similar Documents

Publication Publication Date Title
US12624033B2 (en) KRAS inhibitors
US12599672B2 (en) KRAS proteolysis targeting chimeras
CA2947338C (en) Multi-fluoro-substituted compound as bruton's tyrosine kinase (btk) inhibitor
CA3247639A1 (en) CHIMERAS TARGET KRAS-G12D PROTEOLYSIS
EP2912037B1 (en) 2-aminopyridine compounds
US12378218B2 (en) Cyclopentane compounds
AU2015236855B2 (en) Pyridyl piperidines
EA039783B1 (ru) ПРОИЗВОДНЫЕ ТИРОЗИНАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
HK1197067A1 (en) Cdk inhibitors
NZ578977A (en) 2-aminopyrimidine modulators of the histamine h4 receptor
EP3971176A1 (en) Aromatic amine ar and bet targeting protein degradation chimera compound and use
EP3183239B1 (en) Indazoles
CA2875494A1 (en) 2h-imidazol-4-amine compounds and their use as bace inhibitors
CN122036605A (zh) Gpr39蛋白的拮抗剂
WO2011083316A1 (en) Benzazepine derivatives for the treatment of central nervous system disorders
HK40047027A (en) Cyclopentane compounds
HK40047027B (en) Cyclopentane compounds
AU2016218569A1 (en) Pyrimidine derivatives for use in the treatment of cancer
RU2794997C9 (ru) Соединения циклопентана
RU2794997C2 (ru) Соединения циклопентана
HK40047026A (en) Cyclopentane compounds
WO2024233747A1 (en) Heteroaryl compounds as ligand directed degraders of irak4
CN121219279A (zh) 磺酰胺及砜的氟化环状衍生物以及其组成物与方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)